Trial Profile
A Danish population-based cohort study assessing the effectiveness of denosumab versus alendronate therapy by evaluating risk of osteoporotic fractures in new users
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Osteoporosis
- Focus Therapeutic Use
- 21 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management